-
1
-
-
0028247491
-
Genetic alterations in sporadic renal-cell carcinoma: Molecular analyses of tumor suppressor gene harboring chromosomal regions 3p, 5q, and 17p
-
Brauch H, Pomer S, Hieronymus T, Schadt T, Lohrke H, Komitowski D. Genetic alterations in sporadic renal-cell carcinoma: molecular analyses of tumor suppressor gene harboring chromosomal regions 3p, 5q, and 17p. World J. Urol. 12(3), 162-168 (1994).
-
(1994)
World J. Urol.
, vol.12
, Issue.3
, pp. 162-168
-
-
Brauch, H.1
Pomer, S.2
Hieronymus, T.3
Schadt, T.4
Lohrke, H.5
Komitowski, D.6
-
2
-
-
84862874665
-
Second-line systemic therapy for the treatment of metastatic renal cell cancer
-
Kruck S, Bedke J, Kuczyk MA, Merseburger AS. Second-line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev. Anticancer. Ther. 12(6), 777-785 (2012).
-
(2012)
Expert Rev. Anticancer. Ther.
, vol.12
, Issue.6
, pp. 777-785
-
-
Kruck, S.1
Bedke, J.2
Kuczyk, M.A.3
Merseburger, A.S.4
-
3
-
-
77955493600
-
EAU guidelines on renal cell carcinoma: The 2010 update
-
Ljungberg B, Cowan NC, Hanbury DC et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur. Urol. 58(3), 398-406 (2010).
-
(2010)
Eur. Urol.
, vol.58
, Issue.3
, pp. 398-406
-
-
Ljungberg, B.1
Cowan, N.C.2
Hanbury, D.C.3
-
4
-
-
0024381610
-
Spontaneous regression in non-Hodgkin's lymphoma: Clinical and pathogenetic considerations
-
Drobyski WR, Qazi R. Spontaneous regression in non-Hodgkin's lymphoma: clinical and pathogenetic considerations. Am. J. Hematol. 31(2), 138-141 (1989).
-
(1989)
Am. J. Hematol.
, vol.31
, Issue.2
, pp. 138-141
-
-
Drobyski, W.R.1
Qazi, R.2
-
5
-
-
0022501385
-
Regression of metastatic renal cell carcinoma: A case report and literature review
-
Kavoussi LR, Levine SR, Kadmon D, Fair WR. Regression of metastatic renal cell carcinoma: a case report and literature review. J. Urol. 135(5), 1005-1007 (1986).
-
(1986)
J. Urol.
, vol.135
, Issue.5
, pp. 1005-1007
-
-
Kavoussi, L.R.1
Levine, S.R.2
Kadmon, D.3
Fair, W.R.4
-
6
-
-
84893663818
-
Targeted therapy in renal cell carcinoma: Moving from molecular agents to specific immunotherapy
-
doi:10.1007/s00345-013-1033-3 (Epub ahead of print)
-
Bedke J, Gouttefangeas C, Singh-Jasuja H, Stevanovic S, Behnes CL, Stenzl A. Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World J. Urol. doi:10.1007/s00345-013-1033-3 (2013) (Epub ahead of print).
-
(2013)
World J. Urol.
-
-
Bedke, J.1
Gouttefangeas, C.2
Singh-Jasuja, H.3
Stevanovic, S.4
Behnes, C.L.5
Stenzl, A.6
-
7
-
-
84877898781
-
Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches
-
Bockorny B, Dasanu CA. Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches. Expert Opin. Biol. Ther. 13(6), 911-925 (2013).
-
(2013)
Expert Opin. Biol. Ther.
, vol.13
, Issue.6
, pp. 911-925
-
-
Bockorny, B.1
Dasanu, C.A.2
-
8
-
-
79952284127
-
Hallmarks of cancer: The next generation
-
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
-
(2011)
Cell
, vol.144
, Issue.5
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.A.2
-
9
-
-
84871504824
-
A vaccine in renal cell carcinoma: Are we nearing reality?
-
Bedke J, Gouttefangeas C, Kruck S, Stenzl A. A vaccine in renal cell carcinoma: are we nearing reality? Expert Rev. Anticancer. Ther. 12(12), 1503-1505 (2012).
-
(2012)
Expert Rev. Anticancer. Ther.
, vol.12
, Issue.12
, pp. 1503-1505
-
-
Bedke, J.1
Gouttefangeas, C.2
Kruck, S.3
Stenzl, A.4
-
10
-
-
0042914703
-
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer
-
Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21(16), 3127-3132 (2003).
-
(2003)
J. Clin. Oncol.
, vol.21
, Issue.16
, pp. 3127-3132
-
-
Yang, J.C.1
Sherry, R.M.2
Steinberg, S.M.3
-
11
-
-
33644784733
-
IL-2 administration increases CD4+ CD25 (hi) Foxp3+ regulatory T cells in cancer patients
-
Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25 (hi) Foxp3+ regulatory T cells in cancer patients. Blood 107(6), 2409-2414 (2006).
-
(2006)
Blood
, vol.107
, Issue.6
, pp. 2409-2414
-
-
Ahmadzadeh, M.1
Rosenberg, S.A.2
-
12
-
-
34247524959
-
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer
-
van der Vliet HJ, Koon HB, Yue SC et al. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin. Cancer Res. 13(7), 2100-2108 (2007).
-
(2007)
Clin. Cancer Res.
, vol.13
, Issue.7
, pp. 2100-2108
-
-
Van Der-Vliet, H.J.1
Koon, H.B.2
Yue, S.C.3
-
14
-
-
0037108856
-
Integrated functional genomics approach for the design of patient-individual antitumor vaccines
-
Weinschenk T, Gouttefangeas C, Schirle M et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 62(20), 5818-5827 (2002).
-
(2002)
Cancer Res.
, vol.62
, Issue.20
, pp. 5818-5827
-
-
Weinschenk, T.1
Gouttefangeas, C.2
Schirle, M.3
-
15
-
-
0026322151
-
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
-
van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038), 1643-1647 (1991).
-
(1991)
Science
, vol.254
, Issue.5038
, pp. 1643-1647
-
-
Van Der-Bruggen, P.1
Traversari, C.2
Chomez, P.3
-
16
-
-
84884268998
-
IMA901: A peptide vaccine in renal cell carcinoma
-
Bedke J, Stenzl A. IMA901: a peptide vaccine in renal cell carcinoma. Expert opin. Investig. Drugs 22(10), 1329-1336 (2013).
-
(2013)
Expert Opin. Investig. Drugs
, vol.22
, Issue.10
, pp. 1329-1336
-
-
Bedke, J.1
Stenzl, A.2
-
17
-
-
84864662070
-
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
-
Walter S, Weinschenk T, Stenzl A et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18, 1254-1261 (2012).
-
(2012)
Nat Med
, vol.18
, pp. 1254-1261
-
-
Walter, S.1
Weinschenk, T.2
Stenzl, A.3
-
18
-
-
80053343071
-
Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy
-
Seremet T, Brasseur F, Coulie PG. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. Cancer J. 17(5), 325-330 (2011).
-
(2011)
Cancer J.
, vol.17
, Issue.5
, pp. 325-330
-
-
Seremet, T.1
Brasseur, F.2
Coulie, P.G.3
-
19
-
-
79959568681
-
Vaccination therapy in renal cell carcinoma: Current position and future options in metastatic and localized disease
-
Brookman-May S, Burger M, Wieland WF, Rossler W, May M, Denzinger S. Vaccination therapy in renal cell carcinoma: current position and future options in metastatic and localized disease. Expert Rev. Vaccines 10(6), 837-852 (2011).
-
(2011)
Expert Rev. Vaccines
, vol.10
, Issue.6
, pp. 837-852
-
-
Brookman-May, S.1
Burger, M.2
Wieland, W.F.3
Rossler, W.4
May, M.5
Denzinger, S.6
-
20
-
-
77955066199
-
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
-
Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).
-
(2010)
N. Engl. J. Med.
, vol.363
, Issue.5
, pp. 411-422
-
-
Kantoff, P.W.1
Higano, C.S.2
Shore, N.D.3
-
21
-
-
34447123763
-
Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer
-
Small EJ, Sacks N, Nemunaitis J et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res. 13(13), 3883-3891 (2007).
-
(2007)
Clin. Cancer Res.
, vol.13
, Issue.13
, pp. 3883-3891
-
-
Small, E.J.1
Sacks, N.2
Nemunaitis, J.3
-
22
-
-
33745247366
-
Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients
-
Wierecky J, Muller MR, Wirths S et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 66(11), 5910-5918 (2006).
-
(2006)
Cancer Res.
, vol.66
, Issue.11
, pp. 5910-5918
-
-
Wierecky, J.1
Muller, M.R.2
Wirths, S.3
-
23
-
-
70350010317
-
Immunotherapeutic strategies in kidney cancer-when TKIs are not enough
-
Biswas S, Eisen T. Immunotherapeutic strategies in kidney cancer-when TKIs are not enough. Nat. Rev. Clin. Oncol. 6(8), 478-487 (2009).
-
(2009)
Nat. Rev. Clin. Oncol.
, vol.6
, Issue.8
, pp. 478-487
-
-
Biswas, S.1
Eisen, T.2
-
24
-
-
10744230275
-
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial
-
Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363(9409), 594-599 (2004).
-
(2004)
Lancet
, vol.363
, Issue.9409
, pp. 594-599
-
-
Jocham, D.1
Richter, A.2
Hoffmann, L.3
-
25
-
-
46749131796
-
Vitespen: A vaccine for renal cancer?
-
Yang JC. Vitespen: a vaccine for renal cancer? Lancet 372(9633), 92-93 (2008).
-
(2008)
Lancet
, vol.372
, Issue.9633
, pp. 92-93
-
-
Yang, J.C.1
-
26
-
-
46749085802
-
An adjuvant autologous therapeutic vaccine (HSPPC-96; Vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: A multicentre, open-label, randomised phase III trial
-
Wood C, Srivastava P, Bukowski R et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372(9633), 145-154 (2008).
-
(2008)
Lancet
, vol.372
, Issue.9633
, pp. 145-154
-
-
Wood, C.1
Srivastava, P.2
Bukowski, R.3
-
27
-
-
79960359817
-
A phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) in combination with sunitinib
-
Amin A, Dudek A, Logan T et al. A phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) in combination with sunitinib. J. Clin. Oncol. (Meeting Abstracts), 28(15 Suppl.), 4514 (2010).
-
(2010)
J. Clin. Oncol. (Meeting Abstracts)
, vol.28
, Issue.15 SUPPL.
, pp. 4514
-
-
Amin, A.1
Dudek, A.2
Logan, T.3
-
28
-
-
84880944039
-
Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC)
-
Abstract 357
-
Amin A, Dudek A, Logan T et al. Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC). J. Clin. Oncol. 31(Suppl. 6), Abstract 357 (2013).
-
(2013)
J. Clin. Oncol.
, vol.31
, Issue.SUPPL.. 6
-
-
Amin, A.1
Dudek, A.2
Logan, T.3
-
29
-
-
79961093008
-
Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib
-
Abstract 2532
-
Figlin RA, Nicolette CA, Amin A et al. Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib. J. Clin. Oncol. 29(Suppl.), Abstract 2532 (2011).
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.SUPPL..
-
-
Figlin, R.A.1
Nicolette, C.A.2
Amin, A.3
-
30
-
-
70350537020
-
Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas
-
Attig S, Hennenlotter J, Pawelec G et al. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res. 69(21), 8412-8419 (2009).
-
(2009)
Cancer Res.
, vol.69
, Issue.21
, pp. 8412-8419
-
-
Attig, S.1
Hennenlotter, J.2
Pawelec, G.3
-
31
-
-
0025360886
-
Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma
-
Osband ME, Lavin PT, Babayan RK et al. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet 335(8696), 994-998 (1990).
-
(1990)
Lancet
, vol.335
, Issue.8696
, pp. 994-998
-
-
Osband, M.E.1
Lavin, P.T.2
Babayan, R.K.3
-
32
-
-
84865554296
-
Emerging immunotherapies for renal cell carcinoma
-
Escudier B. Emerging immunotherapies for renal cell carcinoma. Ann. Oncol. 23(Suppl. 8), viii35-40 (2012).
-
(2012)
Ann. Oncol.
, vol.23
, Issue.SUPPL.. 8
-
-
Escudier, B.1
-
33
-
-
0032784492
-
Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma
-
Figlin RA, Thompson JA, Bukowski RM et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J. Clin. Oncol. 17(8), 2521-2529 (1999).
-
(1999)
J. Clin. Oncol.
, vol.17
, Issue.8
, pp. 2521-2529
-
-
Figlin, R.A.1
Thompson, J.A.2
Bukowski, R.M.3
-
34
-
-
84877129770
-
Adoptive cellular immunotherapy in metastatic renal cell carcinoma: A systematic review and meta-analysis
-
Tang X, Liu T, Zang X et al. Adoptive cellular immunotherapy in metastatic renal cell carcinoma: a systematic review and meta-analysis. PLoS ONE 8(5), e62847 (2013).
-
(2013)
PLoS ONE
, vol.8
, Issue.5
-
-
Tang, X.1
Liu, T.2
Zang, X.3
-
35
-
-
22144496809
-
Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes
-
Engels B, Noessner E, Frankenberger B, Blankenstein T, Schendel DJ, Uckert W. Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes. Hum. Gene Ther. 16(7), 799-810 (2005).
-
(2005)
Hum. Gene Ther.
, vol.16
, Issue.7
, pp. 799-810
-
-
Engels, B.1
Noessner, E.2
Frankenberger, B.3
Blankenstein, T.4
Schendel, D.J.5
Uckert, W.6
-
36
-
-
67049156789
-
Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer
-
Feyerabend S, Stevanovic S, Gouttefangeas C et al. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 69(9), 917-927 (2009).
-
(2009)
Prostate
, vol.69
, Issue.9
, pp. 917-927
-
-
Feyerabend, S.1
Stevanovic, S.2
Gouttefangeas, C.3
-
37
-
-
0025109257
-
Immunohistological distribution of 5T4 antigen in normal and malignant tissues
-
Southall PJ, Boxer GM, Bagshawe KD, Hole N, Bromley M, Stern PL. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br. J. Cancer 61(1), 89-95 (1990).
-
(1990)
Br. J. Cancer
, vol.61
, Issue.1
, pp. 89-95
-
-
Southall, P.J.1
Boxer, G.M.2
Bagshawe, K.D.3
Hole, N.4
Bromley, M.5
Stern, P.L.6
-
38
-
-
0029903794
-
Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells
-
Carsberg CJ, Myers KA, Stern PL. Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells. Int. J. Cancer 68(1), 84-92 (1996).
-
(1996)
Int. J. Cancer
, vol.68
, Issue.1
, pp. 84-92
-
-
Carsberg, C.J.1
Myers, K.A.2
Stern, P.L.3
-
39
-
-
84888237576
-
Identification of preand post-treatment markers, clinical, and laboratory parameters associated with outcome in renal cancer patients treated with MVA-5T4
-
Said R, Amato RJ. Identification of preand post-treatment markers, clinical, and laboratory parameters associated with outcome in renal cancer patients treated with MVA-5T4. Front. Oncol. 3, 185 (2013).
-
(2013)
Front. Oncol.
, vol.3
, pp. 185
-
-
Said, R.1
Amato, R.J.2
-
40
-
-
78349284842
-
Vaccination of metastatic renal cancer patients with MVA-5T4: A randomized, double-blind, placebo-controlled phase III study
-
Amato RJ, Hawkins RE, Kaufman HL et al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin. Cancer Res. 16(22), 5539-5547 (2010).
-
(2010)
Clin. Cancer Res.
, vol.16
, Issue.22
, pp. 5539-5547
-
-
Amato, R.J.1
Hawkins, R.E.2
Kaufman, H.L.3
-
41
-
-
84871004671
-
Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (Tro Vax)
-
Harrop R, Treasure P, de Belin J et al. Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (Tro Vax). Cancer Immunol. Immunother. 61(12), 2283-2294 (2012).
-
(2012)
Cancer Immunol. Immunother.
, vol.61
, Issue.12
, pp. 2283-2294
-
-
Harrop, R.1
Treasure, P.2
De Belin, J.3
-
42
-
-
78149254368
-
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma
-
Sampson JH, Heimberger AB, Archer GE et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28(31), 4722-4729 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.31
, pp. 4722-4729
-
-
Sampson, J.H.1
Heimberger, A.B.2
Archer, G.E.3
-
43
-
-
73149092567
-
Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria
-
Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15(23), 7412-7420 (2009).
-
(2009)
Clin. Cancer Res.
, vol.15
, Issue.23
, pp. 7412-7420
-
-
Wolchok, J.D.1
Hoos, A.2
O'Day, S.3
-
44
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
-
(2012)
N. Engl. J. Med.
, vol.366
, Issue.26
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
-
45
-
-
78651292217
-
Allele frequency net: A database and online repository for immune gene frequencies in worldwide populations
-
Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res. 39(Database issue), D913-919 (2011).
-
(2011)
Nucleic Acids Res.
, vol.39
-
-
Gonzalez-Galarza, F.F.1
Christmas, S.2
Middleton, D.3
Jones, A.R.4
-
46
-
-
84871503916
-
Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal cell carcinoma
-
Bedke J, Laske K, Feyerabend S et al. Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal cell carcinoma. Eur. Urol. Suppl. 11, e76 (2012).
-
(2012)
Eur. Urol. Suppl.
, vol.11
-
-
Bedke, J.1
Laske, K.2
Feyerabend, S.3
-
47
-
-
33645697721
-
A phase i trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma
-
Uemura H, Fujimoto K, Tanaka M et al. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin. Cancer Res. 12(6), 1768-1775 (2006).
-
(2006)
Clin. Cancer Res.
, vol.12
, Issue.6
, pp. 1768-1775
-
-
Uemura, H.1
Fujimoto, K.2
Tanaka, M.3
-
48
-
-
55249100794
-
Bevacizumab: Direct anti-VEGF therapy in renal cell carcinoma
-
Escudier B, Cosaert J, Pisa P. Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma. Expert Rev. Anticancer Ther. 8(10), 1545-1557 (2008).
-
(2008)
Expert Rev. Anticancer Ther.
, vol.8
, Issue.10
, pp. 1545-1557
-
-
Escudier, B.1
Cosaert, J.2
Pisa, P.3
-
49
-
-
77952300540
-
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival
-
Escudier B, Bellmunt J, Negrier S et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 28(13), 2144-2150 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.13
, pp. 2144-2150
-
-
Escudier, B.1
Bellmunt, J.2
Negrier, S.3
-
50
-
-
77952318310
-
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206
-
Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 28(13), 2137-2143 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.13
, pp. 2137-2143
-
-
Rini, B.I.1
Halabi, S.2
Rosenberg, J.E.3
-
51
-
-
84883331795
-
A multinational phase II trial of bevacizumab with low-dose interferonalpha2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN
-
Melichar B, Bracarda S, Matveev V et al. A multinational phase II trial of bevacizumab with low-dose interferonalpha2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. Ann. Oncol. 24(9), 2396-2402 (2013).
-
(2013)
Ann. Oncol.
, vol.24
, Issue.9
, pp. 2396-2402
-
-
Melichar, B.1
Bracarda, S.2
Matveev, V.3
-
52
-
-
0037314709
-
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy
-
Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9(2), 802-811 (2003).
-
(2003)
Clin. Cancer Res.
, vol.9
, Issue.2
, pp. 802-811
-
-
Bui, M.H.1
Seligson, D.2
Han, K.R.3
-
53
-
-
0030017852
-
Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors
-
Surfus JE, Hank JA, Oosterwijk E et al. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J. Immunother. Emphasis Tumor Immunol. 19(3), 184-191 (1996).
-
(1996)
J. Immunother. Emphasis Tumor Immunol.
, vol.19
, Issue.3
, pp. 184-191
-
-
Surfus, J.E.1
Hank, J.A.2
Oosterwijk, E.3
-
54
-
-
84878454886
-
Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma
-
Oosterwijk-Wakka JC, Boerman OC, Mulders PF, Oosterwijk E. Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int. J. Mol. Sci. 14(6), 11402-11423 (2013).
-
(2013)
Int. J. Mol. Sci.
, vol.14
, Issue.6
, pp. 11402-11423
-
-
Oosterwijk-Wakka, J.C.1
Boerman, O.C.2
Mulders, P.F.3
Oosterwijk, E.4
-
55
-
-
84888227525
-
ARISER: A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC-Results and implications for adjuvant clinical trials
-
Abstract 4507
-
Belldegrun AS, Chamie K, Kloepfer P et al. ARISER: a randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC-Results and implications for adjuvant clinical trials. J. Clin. Oncol. 31(Suppl.), Abstract 4507 (2013).
-
(2013)
J. Clin. Oncol.
, vol.31
, Issue.SUPPL..
-
-
Belldegrun, A.S.1
Chamie, K.2
Kloepfer, P.3
-
56
-
-
14944360112
-
Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4
-
Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat. Immunol. 6(3), 280-286 (2005).
-
(2005)
Nat. Immunol.
, vol.6
, Issue.3
, pp. 280-286
-
-
Probst, H.C.1
McCoy, K.2
Okazaki, T.3
Honjo, T.4
Van Den-Broek, M.5
-
57
-
-
84877940678
-
Trial watch: Peptide vaccines in cancer therapy
-
Vacchelli E, Martins I, Eggermont A et al. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 1(9), 1557-1576 (2012).
-
(2012)
Oncoimmunology
, vol.1
, Issue.9
, pp. 1557-1576
-
-
Vacchelli, E.1
Martins, I.2
Eggermont, A.3
-
59
-
-
33847258205
-
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
-
Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann. Oncol. 18(2), 226-232 (2007).
-
(2007)
Ann. Oncol.
, vol.18
, Issue.2
, pp. 226-232
-
-
Parmiani, G.1
Castelli, C.2
Pilla, L.3
Santinami, M.4
Colombo, M.P.5
Rivoltini, L.6
-
60
-
-
0027538181
-
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
-
Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90(8), 3539-3543 (1993).
-
(1993)
Proc. Natl Acad. Sci. USA
, vol.90
, Issue.8
, pp. 3539-3543
-
-
Dranoff, G.1
Jaffee, E.2
Lazenby, A.3
-
61
-
-
0034047619
-
Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand
-
Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res. 60(12), 3239-3246 (2000).
-
(2000)
Cancer Res.
, vol.60
, Issue.12
, pp. 3239-3246
-
-
Mach, N.1
Gillessen, S.2
Wilson, S.B.3
Sheehan, C.4
Mihm, M.5
Dranoff, G.6
-
62
-
-
0031570843
-
Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colonystimulating factor gene-modified tumor cells
-
Qin Z, Noffz G, Mohaupt M, Blankenstein T. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colonystimulating factor gene-modified tumor cells. J. Immunol. 159(2), 770-776 (1997).
-
(1997)
J. Immunol.
, vol.159
, Issue.2
, pp. 770-776
-
-
Qin, Z.1
Noffz, G.2
Mohaupt, M.3
Blankenstein, T.4
-
63
-
-
0029833732
-
Mechanisms of immune suppression in patients with head and neck cancer: Influence on the immune infiltrate of the cancer
-
Young MR, Wright MA, Lozano Y, Matthews JP, Benefield J, Prechel MM. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int. J. Cancer 67(3), 333-338 (1996).
-
(1996)
Int. J. Cancer
, vol.67
, Issue.3
, pp. 333-338
-
-
Young, M.R.1
Wright, M.A.2
Lozano, Y.3
Matthews, J.P.4
Benefield, J.5
Prechel, M.M.6
-
64
-
-
0031570886
-
Myeloid differentiation treatment to diminish the presence of immune-suppressive CD34+ cells within human head and neck squamous cell carcinomas
-
Young MR, Wright MA, Pandit R. Myeloid differentiation treatment to diminish the presence of immune-suppressive CD34+ cells within human head and neck squamous cell carcinomas. J. Immunol. 159(2), 990-996 (1997).
-
(1997)
J. Immunol.
, vol.159
, Issue.2
, pp. 990-996
-
-
Young, M.R.1
Wright, M.A.2
Pandit, R.3
-
65
-
-
4344590947
-
High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells
-
Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 64(17), 6337-6343 (2004).
-
(2004)
Cancer Res.
, vol.64
, Issue.17
, pp. 6337-6343
-
-
Serafini, P.1
Carbley, R.2
Noonan, K.A.3
Tan, G.4
Bronte, V.5
Borrello, I.6
-
66
-
-
0030944023
-
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer
-
Simons JW, Jaffee EM, Weber CE et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57(8), 1537-1546 (1997).
-
(1997)
Cancer Res.
, vol.57
, Issue.8
, pp. 1537-1546
-
-
Simons, J.W.1
Jaffee, E.M.2
Weber, C.E.3
-
67
-
-
0033998594
-
Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor
-
Spitler LE, Grossbard ML, Ernstoff MS et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol. 18(8), 1614-1621 (2000).
-
(2000)
J. Clin. Oncol.
, vol.18
, Issue.8
, pp. 1614-1621
-
-
Spitler, L.E.1
Grossbard, M.L.2
Ernstoff, M.S.3
-
68
-
-
0033153295
-
GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial
-
Simmons SJ, Tjoa BA, Rogers M et al. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate 39(4), 291-297 (1999).
-
(1999)
Prostate
, vol.39
, Issue.4
, pp. 291-297
-
-
Simmons, S.J.1
Tjoa, B.A.2
Rogers, M.3
-
69
-
-
34248194231
-
Tregs and rethinking cancer immunotherapy
-
Curiel TJ. Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117(5), 1167-1174 (2007).
-
(2007)
J. Clin. Invest.
, vol.117
, Issue.5
, pp. 1167-1174
-
-
Curiel, T.J.1
-
70
-
-
58149332680
-
Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma
-
Kusmartsev S, Su Z, Heiser A et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 14(24), 8270-8278 (2008).
-
(2008)
Clin. Cancer Res.
, vol.14
, Issue.24
, pp. 8270-8278
-
-
Kusmartsev, S.1
Su, Z.2
Heiser, A.3
-
71
-
-
47949096781
-
Cancer-related inflammation
-
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 454(7203), 436-444 (2008).
-
(2008)
Nature
, vol.454
, Issue.7203
, pp. 436-444
-
-
Mantovani, A.1
Allavena, P.2
Sica, A.3
Balkwill, F.4
-
72
-
-
47949090079
-
The role of myeloid cells in the promotion of tumour angiogenesis
-
Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8(8), 618-631 (2008).
-
(2008)
Nat. Rev. Cancer
, vol.8
, Issue.8
, pp. 618-631
-
-
Murdoch, C.1
Muthana, M.2
Coffelt, S.B.3
Lewis, C.E.4
-
73
-
-
84880936480
-
Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901
-
Walter S, Weinschenk T, Reinhardt C, Singh-Jasuja H. Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901. Oncoimmunology 2(1), e22246 (2013).
-
(2013)
Oncoimmunology
, vol.2
, Issue.1
-
-
Walter, S.1
Weinschenk, T.2
Reinhardt, C.3
Singh-Jasuja, H.4
-
74
-
-
84881233953
-
Cyclophosphamide induces a type i interferon-associated sterile inflammatory response signature in cancer patients' blood cells: Implications for cancer chemoimmunotherapy
-
Moschella F, Torelli GF, Valentini M et al. Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapy. Clin. Cancer Res. 19(15), 4249-4261 (2013).
-
(2013)
Clin. Cancer Res.
, vol.19
, Issue.15
, pp. 4249-4261
-
-
Moschella, F.1
Torelli, G.F.2
Valentini, M.3
-
75
-
-
84878589185
-
Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma
-
Sevko A, Sade-Feldman M, Kanterman J et al. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J. Investig. Dermatol. 133(6), 1610-1619 (2013).
-
(2013)
J. Investig. Dermatol.
, vol.133
, Issue.6
, pp. 1610-1619
-
-
Sevko, A.1
Sade-Feldman, M.2
Kanterman, J.3
-
76
-
-
58149179532
-
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients
-
Finke JH, Rini B, Ireland J et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin. Cancer Res. 14(20), 6674-6682 (2008).
-
(2008)
Clin. Cancer Res.
, vol.14
, Issue.20
, pp. 6674-6682
-
-
Finke, J.H.1
Rini, B.2
Ireland, J.3
-
77
-
-
63549105681
-
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients
-
Ko JS, Zea AH, Rini BI et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15(6), 2148-2157 (2009).
-
(2009)
Clin. Cancer Res.
, vol.15
, Issue.6
, pp. 2148-2157
-
-
Ko, J.S.1
Zea, A.H.2
Rini, B.I.3
-
78
-
-
84878758972
-
Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors
-
Stehle F, Schulz K, Fahldieck C et al. Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. J. Biol. Chem. 288(23), 16334-16347 (2013).
-
(2013)
J. Biol. Chem.
, vol.288
, Issue.23
, pp. 16334-16347
-
-
Stehle, F.1
Schulz, K.2
Fahldieck, C.3
-
79
-
-
47049127786
-
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
-
Hipp MM, Hilf N, Walter S et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111(12), 5610-5620 (2008).
-
(2008)
Blood
, vol.111
, Issue.12
, pp. 5610-5620
-
-
Hipp, M.M.1
Hilf, N.2
Walter, S.3
-
80
-
-
84866874594
-
Immunological effects of multikinase inhibitors for kidney cancer: A clue for integration with cellular therapies?
-
Porta C, Paglino C, Imarisio I, Ganini C, Pedrazzoli P. Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies? J. Cancer. 2, 333-338 (2011).
-
(2011)
J. Cancer.
, vol.2
, pp. 333-338
-
-
Porta, C.1
Paglino, C.2
Imarisio, I.3
Ganini, C.4
Pedrazzoli, P.5
-
81
-
-
0035056017
-
CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy
-
Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19, 565-594 (2001).
-
(2001)
Annu. Rev. Immunol.
, vol.19
, pp. 565-594
-
-
Chambers, C.A.1
Kuhns, M.S.2
Egen, J.G.3
Allison, J.P.4
-
82
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
-
(2010)
N. Engl. J. Med.
, vol.363
, Issue.8
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
-
83
-
-
37349072460
-
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
-
Yang JC, Hughes M, Kammula U et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. 30(8), 825-830 (2007).
-
(2007)
J. Immunother.
, vol.30
, Issue.8
, pp. 825-830
-
-
Yang, J.C.1
Hughes, M.2
Kammula, U.3
-
84
-
-
18544380239
-
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
-
Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8(8), 793-800 (2002).
-
(2002)
Nat. Med.
, vol.8
, Issue.8
, pp. 793-800
-
-
Dong, H.1
Strome, S.E.2
Salomao, D.R.3
-
85
-
-
0038273853
-
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
-
Curiel TJ, Wei S, Dong H et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9(5), 562-567 (2003).
-
(2003)
Nat. Med.
, vol.9
, Issue.5
, pp. 562-567
-
-
Curiel, T.J.1
Wei, S.2
Dong, H.3
-
86
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012).
-
(2012)
N. Engl. J. Med.
, vol.366
, Issue.26
, pp. 2455-2465
-
-
Brahmer, J.R.1
Tykodi, S.S.2
Chow, L.Q.3
-
87
-
-
84879777241
-
Nivolumab plus ipilimumab in advanced melanoma
-
Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122-133 (2013).
-
(2013)
N. Engl. J. Med.
, vol.369
, Issue.2
, pp. 122-133
-
-
Wolchok, J.D.1
Kluger, H.2
Callahan, M.K.3
-
88
-
-
37349077911
-
The CIMT-monitoring panel: A two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays
-
Britten CM, Gouttefangeas C, Welters MJ et al. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol. Immunother. 57(3), 289-302 (2008).
-
(2008)
Cancer Immunol. Immunother.
, vol.57
, Issue.3
, pp. 289-302
-
-
Britten, C.M.1
Gouttefangeas, C.2
Welters, M.J.3
|